Evidence map›Paper›PMID 24477853›Full record

ArticleClinical and vaccine immunology : CVI2014

Performance of the BioPlex 2200 flow immunoassay in critical cases of serodiagnosis of toxoplasmosis.

Nicolas Guigue, Jean Menotti, Samia Hamane, Francis Derouin, Yves Jean-François Garin

Open access · diamondAbstract readComparative StudyEvaluation Study
In one paragraph

Article in Clinical and vaccine immunology : CVI, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Diagnostic applications of microsphere-based flow cytometry: A review.Experimental biology and medicine (Maywood, N.J.) · 2022
    Review
  4. Serological and molecular rapid diagnostic tests for Toxoplasma infection in humans and animals.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2020
    Review
  5. Detection of Anti-Analytical chemistry · 2019
    Article
  6. Detection of Salmonid IgM Specific to theFrontiers in immunology · 2019
    Article
  7. Article
  8. Article
  9. Article
  10. ELISA in the multiplex era: potentials and pitfalls.Proteomics. Clinical applications · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Nicolas GuigueLaboratoire de Parasitologie et de Mycologie, Hôpital Saint Louis, Assistance Publique-Hôpitaux de Paris et Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Jean Menotti
Samia Hamane
Francis Derouin
Yves Jean-François Garin
Hôpital Saint-Louis · FRDélégation Paris 7 · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The BioPlex 2200 automated analyzer (Bio-Rad Laboratories, Hercules, CA) is a recently developed multiplex analyzer that enables the detection of anti-Toxoplasma, -rubella, and -cytomegalovirus antibodies in the same assay. The aim of this study was to compare this new technology (using the BioPlex 2200 ToRC IgG/IgM kit) in critical cases of serodiagnosis of toxoplasmosis (acute, chronic, or congenital infections and cases with discrepant results) to the technologies used in our routine practice, i.e., the Platelia IgG/IgM enzyme-linked immunosorbent assays (ELISAs) (Bio-Rad Laboratories) and the Toxo-Screen direct agglutination assay (bioMérieux, Lyon, France). Overall, most cases of false-positive/negative results obtained with the Platelia IgG or Toxo-Screen assay were corrected by the BioPlex 2200 ToRC IgG (87.5%). Furthermore, the analysis of 35 sequences of sera showed a trend toward a more rapid decrease of IgM titers by BioPlex 2200 than by Platelia. These results for IgM detection can be explained by a weaker detection of residual IgM. Indeed, among 23 serum samples from patients with probable past infection with long-lasting IgM (Platelia M positive and IgG avidity index, ≥0.5), the BioPlex 2200 Toxoplasma IgM assay was positive for only 11 serum samples. In our panel of critical cases comprising 156 serum and 6 cord blood samples from 103 patients with acute, chronic, or congenital infection, the BioPlex 2200 IgG assay was a sensitive (97.8%) and specific (91.3%) method for IgG detection. The high specificity (97.4%) of IgM detection combined with the shorter kinetics of IgM titers may considerably reduce the number of residual IgM detections, thus yielding more precise diagnoses of acute infections.

Indexed as

Antibodies, ProtozoanAutomation, LaboratoryHumansImmunoassayImmunoglobulin GImmunoglobulin MSensitivity and SpecificitySerologic TestsToxoplasmosisAntibodies, ProtozoanImmunoglobulin GImmunoglobulin M

Identifiers

PMID24477853
PMCPMC3993110
OpenAlexW2130711431

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.